To include your compound in the COVID-19 Resource Center, submit it here.

Cabozantinib: Interim Phase II data

Updated interim data from 490 evaluable patients with various solid tumors in the lead-in stage of an ongoing, adaptive, international Phase II trial showed that once-daily oral cabozantinib led to 12-week overall disease control rates (DCRs) of 73%, 68%, 53%, 47%, 45% and 40% for patients with hepatocellular carcinoma (HCC), castration-resistant prostate cancer (CRPC), ovarian cancer, melanoma, breast cancer and non-small cell lung cancer (NSCLC), respectively. Lower 12-week DCRs were observed in patients with small cell lung cancer

Read the full 788 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers